|
Active substance |
niraparib |
|
Holder |
GlaxoSmithKline Pharmaceuticals S.A./N.V. |
|
Status |
Closed |
|
Indication |
maintenance treatment of adult female patients with BRCA1/2 wild-type advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer in response following first-line platinumbased chemotherapy |
|
Public documents |
|
| Approbation amendment | |
|
Last update |
10/08/2022 |
Zejula®
Last updated on 13/09/2024